Lento Bio

Drug Discovery · Biotechnology

Overview

Lento Bio is developing a first-in-class eye drop to reverse presbyopia by restoring lens flexibility. No surgery, no special lenses.

Funding and backers

Total raised
$680k
1 round on record
Latest round
$680k
Seed · Sep 2022 · 4 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
50 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 5, 2022 Raised a round Seed $680k · led by Ichor Life Sciences 2022 Founded
Funding rounds
RoundDateAmountInvestorsSource
Seed Sep 2022 $680k Ichor Life Sciences lead theglobeandmail.com
Registers and programsofficial lists and records that name the company
Legal entity Lento Bio, Inc SEC Form D
Founders and leadersfrom filings, registers and the company's site
Kris BarnesExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Andreessen Horowitz
backs GateBioscience
GV
backs GateBioscience
High-Tech Gründerfonds
backs Draupnir Bio
ARCH Venture Partners
backs GateBioscience
Canaan Partners
backs Draig Therapeutics
Atinum Investment
backs Zymedi
Similar startupsby what they do, their industry and backers
Draig TherapeuticsSeries B $65M · 3 mo ago · Founded 2024 · 501-1000 employees
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
PsileraSeed $8.8M · 5 mo ago · Founded 2021 · 11-50 employees
Psilera is a biotechnology company developing groundbreaking first-in-class treatments for neurological disorders by creating a new class…
Paratus Sciences
We navigate evolutionary data to translate extreme biological adaptations into first-in-class medicines. Learn more about our process.
ORIA Bioscience | Isolated Organelles for Drug DiscoveryFounded 2022
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
Draupnir BioSeed $13M · 2 yr ago
Draupnir Bio is developing new innovative therapies for patients.
Zymedi
Zymedi leverages ARS biology to discover novel therapeutics and first-in-class drugs for patients.

Financials

Total raised
$680k
Latest round
Seed
Funding rounds
1
Funding rounds
Round Announced Amount
Seed 2022 $680k Details

People

Kris Barnes
Executive Officer, Director
SEC Form D
Kenneth Scott
Director
SEC Form D
Kelsey Moody
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data